A 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression in patients with quiescent, non-infectious intermediate, posterior or panuveitis (ENDURE Study)

Woman and Man

| Country :
| organs :
| Specialty :

Extract

To evaluate the efficacy of three dose regimens of subcutaneous AIN457 compared to placebo for maintaining the suppression of intraocular inflammation and the prevention of an active intermediate, posterior or panuveitis recurrence during the withdrawal of concomitant immunosuppressive therapy in adults with quiescent, non-infectious, uveitis affecting the posterior segment desiring to wean from the standard-of-care systemic immunosuppressive therapy required to control their ocular inflammatory disease.

Inclusion criteria

quiescent, non-infectious intermediate, posterior or panuveitis

Kusajili – Clinical trials directory

A 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppressio...